Customer Support: +919024236503

Need Help?

  • Share via whatsapp

How Sucroferric Oxyhydroxide 2500 mg Helps in Chronic Kidney Disease (CKD)

Mar 06, 2025

Introduction

RUDIX SUCRO FE is a phosphate binder containing Sucroferric Oxyhydroxide (2500 mg), primarily used in patients with chronic kidney disease (CKD) who are undergoing dialysis. It helps in controlling serum phosphorus levels, preventing complications such as bone disorders and cardiovascular issues. Phosphorus retention is a common issue in patients with CKD, and RUDIX SUCRO FE plays a critical role in maintaining proper mineral balance.

Key Ingredients

  • Sucroferric Oxyhydroxide (2500 mg): A non-calcium-based phosphate binder that works by reducing phosphate absorption in the gastrointestinal (GI) tract. It contains iron, which binds dietary phosphate and helps in its excretion through feces.

  • Excipients: Other inactive ingredients to aid in tablet formulation and absorption.

Key Benefits

  1. Effective Phosphate Control: Helps lower serum phosphorus levels in patients with end-stage renal disease (ESRD) undergoing hemodialysis or peritoneal dialysis.

  2. Reduced Pill Burden: Unlike traditional phosphate binders, sucroferric oxyhydroxide requires fewer daily doses due to its higher binding capacity.

  3. Minimal Systemic Absorption: The iron in the compound is not significantly absorbed into the bloodstream, reducing the risk of iron overload.

  4. Improved Bone Health: Helps prevent renal osteodystrophy, a condition where bones weaken due to excess phosphorus.

  5. Supports Cardiovascular Health: High phosphate levels contribute to vascular calcification, which increases the risk of heart disease. This medication helps lower such risks.

  6. Better Tolerability: Compared to calcium-based binders, it has a lower risk of hypercalcemia, which can lead to vascular complications.

How Does It Work?

Sucroferric Oxyhydroxide functions as a phosphate-binding agent. After ingestion, it reacts with dietary phosphorus in the stomach and small intestine, forming an insoluble complex that is excreted through feces. This prevents phosphate absorption into the bloodstream, thereby reducing serum phosphorus levels.

Unlike calcium-based phosphate binders, it does not contribute to vascular calcification, making it a safer choice for CKD patients.

Indications

RUDIX SUCRO FE is indicated for:

  • Chronic Kidney Disease (CKD) Stage 5 patients undergoing dialysis.

  • Patients with hyperphosphatemia who require phosphate binding therapy.

  • Individuals with renal osteodystrophy at risk of bone-related complications.

Dosage and Administration

  • Recommended Starting Dose: 500 mg three times daily with meals.

  • Dose Adjustment: Based on serum phosphate levels, the dosage may be increased or decreased under medical supervision.

  • Maximum Dose: Typically not more than 3000 mg/day, depending on individual patient needs.

  • Administration: Tablets should be chewed and not swallowed whole. It is best taken with food for optimal phosphate binding.

Side Effects

While RUDIX SUCRO FE is generally well tolerated, some patients may experience side effects, including:

Common Side Effects:

  • Dark stools: Due to the iron content.

  • Diarrhea: Mild to moderate gastrointestinal upset.

  • Nausea: Can occur in some individuals but usually subsides.

  • Flatulence (Gas): Some patients may experience mild bloating.

Rare but Serious Side Effects:

  • Hypophosphatemia (Low phosphorus levels): Can occur if the dose is too high.

  • Allergic Reactions: Symptoms such as rash, itching, or swelling require immediate medical attention.

  • Iron Overload (Extremely rare): Since systemic iron absorption is minimal, the risk is low, but regular monitoring is advised.

Precautions and Warnings

  • Not for Patients with Hemochromatosis: Since it contains iron, it should be avoided in patients with iron overload disorders.

  • Monitor Serum Phosphate Levels: Regular testing is required to avoid hypophosphatemia.

  • Not for Non-Dialysis CKD Patients: It is specifically formulated for patients undergoing dialysis.

  • Use in Pregnancy and Lactation: Limited data is available; use only under a doctor’s guidance.

  • Drug Interactions: Can interfere with certain medications, including thyroid medications, antibiotics, and certain antivirals.

Comparison with Other Phosphate Binders

Feature RUDIX SUCRO FE (Sucroferric Oxyhydroxide) Sevelamer Carbonate Calcium Acetate
Active Ingredient Sucroferric Oxyhydroxide Sevelamer Calcium Acetate
Calcium Content None None High
Dosing Frequency Lower Higher Higher
Risk of Hypercalcemia No No Yes
Mode of Action Binds phosphate in GI tract Binds phosphate in GI tract Binds phosphate in GI tract
Side Effects Dark stools, diarrhea GI issues Hypercalcemia

Storage Information

  • Keep in a cool, dry place away from moisture and direct sunlight.

  • Store at room temperature (20-25°C).

  • Keep out of reach of children.

Price in India

The Sucroferric Oxyhydroxide 2500 mg price varies based on pack size and pharmacy location. On average, it costs between ₹3,000 - ₹4,500 per bottle (30-90 tablets). Prices may fluctuate based on availability and region.

Frequently Asked Questions (FAQs)

1. Can RUDIX SUCRO FE be taken with other medications?

  • Yes, but it should be taken at least 1 hour before or 2 hours after certain drugs like levothyroxine and antibiotics to avoid interactions.

2. How long does it take to show effects?

  • Phosphate levels begin to lower within 2 weeks of starting treatment.

3. Does it cause weight gain?

  • No, it does not cause weight gain.

4. Is it safe for diabetic patients?

  • Yes, it does not affect blood sugar levels.

5. Can it be taken without food?

  • No, it should always be taken with meals for maximum phosphate binding efficiency.

Conclusion

RUDIX SUCRO FE (Sucroferric Oxyhydroxide 2500 mg) is an effective phosphate binder for patients undergoing dialysis. It helps in controlling serum phosphorus levels, reducing the risk of bone and cardiovascular complications. With minimal side effects and lower pill burden, it is a preferred choice for many CKD patients. Always consult a doctor before starting or adjusting the dosage to ensure optimal result

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW

SHARE WITH

  • Share via whatsapp